CALLIDITAS THERAPEUTICS-ADR (CALT)
US13124Q1067 - ADR
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 973.73M | 1.25B | 955.51M | 996.30M | 753.54M | |||
| Receivables | 188.19M | 80.99M | 11.34M | 22.80M | 49.30M | |||
| Inventories | 20.43M | 3.65M | 889.00K | 0.00 | N/A | |||
| Other Current Assets | 92.80M | 78.47M | 45.03M | 17.75M | 18.29M | |||
| Total Current Assets | 1.28B | 1.41B | 1.01B | 1.04B | 821.13M | |||
| Non-Current Assets | ||||||||
| PPE Net | 54.24M | 31.92M | 39.61M | 5.41M | 6.06M | |||
| Investments And Advances | 7.64M | 6.85M | 3.92M | 2.23M | 1.94M | |||
| Goodwill | 48.58M | 45.78M | N/A | N/A | N/A | |||
| Intangibles | 430.75M | 438.06M | 399.42M | 461.37M | 16.07M | |||
| Other Non-Current Assets | 26.32M | 13.80M | 4.20M | 600.00K | N/A | |||
| Total Non-Current Assets | 584.09M | 540.77M | 447.14M | 469.60M | 24.07M | |||
| TOTAL ASSETS | 1.86B | 1.95B | 1.46B | 1.51B | 845.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 12.54M | 10.37M | 9.59M | 3.91M | 2.49M | |||
| Accrued Expenses | 280.63M | 136.45M | 53.55M | 41.39M | 25.52M | |||
| Accounts Payable | 100.56M | 160.40M | 67.97M | 53.83M | 24.38M | |||
| Other Current Liabilities | 13.42M | 18.01M | 4.33M | 6.50M | 985.00K | |||
| Total Current Liabilities | 407.14M | 325.23M | 135.45M | 105.62M | 53.37M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 966.60M | 728.82M | 213.22M | 878.00K | 3.58M | |||
| Deferred Taxes/Income | 41.64M | 39.75M | 30.86M | 80.00M | N/A | |||
| Other Non-Current Liabilities | 109.06M | 92.90M | 72.11M | 63.66M | 175.00K | |||
| Total Non-Current Liabilities | 1.12B | 861.48M | 316.18M | 190.34M | 3.76M | |||
| TOTAL LIABILITIES | 1.52B | 1.19B | 451.63M | 295.96M | 57.13M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.31B | -1.84B | -1.45B | -924.69M | -488.14M | |||
| Additional Paid In Capital | 2.64B | 2.59B | 2.46B | 2.13B | 1.27B | |||
| Minority Interest | 0.00 | 0.00 | 9.24M | 48.83M | N/A | |||
| Common Shares | 2.38M | 2.38M | 2.09M | 2.00M | 1.55M | |||
| Other Shareholders' Equity | -5.23M | 9.31M | -1.00K | N/A | 1.27B | |||
| Shares Outstanding | 26.84M | 26.84M | 26.17M | 24.97M | 19.35M | |||
| Tangible Book Value per Share | -2.69 | 5.26 | 11.63 | 15.00 | 19.94 | |||
| Total Shareholders' Equity | 334.81M | 766.26M | 1.01B | 1.21B | 788.07M | |||
| TOTAL LIABILITIES AND EQUITY | 1.86B | 1.95B | 1.46B | 1.51B | 845.20M | |||
| Statistics | ||||||||
| Debt/Equity | 2.89 | 0.95 | 0.21 | 0.00 | 0.00 | |||
| Current Ratio | 3.13 | 4.34 | 7.48 | 9.82 | 15.39 | |||
| Return On Assets (ROA) | -25.07% | -21.11% | -34.27% | -28.78% | -3.85% | |||
| Return On Equity (ROE) | -139.24% | -53.80% | -49.62% | -35.81% | -4.13% | |||
All data in SEK